Clinical trials: Biomarker in Early Diagnosis
- Condition Biomarker in Early Diagnosis
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Neovascular Age-related Macular Degeneration
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration…
- Trial name
- IMAGINE (NCT04774926)
- Testing
- Brolucizumab
- Where
- 20 sites in Italy
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This non-randomized, multicenter, open-label study will assess the safety and efficacy of subcutaneously administered trastuzumab in participants with early and locally advanced HER2-positive breast cancer in two sequential…
- Trial name
- SCHEARLY (NCT01940497)
- Testing
- Doxorubicin, Docetaxel, Paclitaxel
- Where
- 54 sites in Italy
- Volunteers
- 240 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
The study will evaluate the effectiveness of ixabepilone when given after doxorubicin plus cyclophosphamide (AC) compared to standard treatment of paclitaxel given after doxorubicin plus cyclophosphamide in patients with early…
- Trial name
- NCT00455533
- Testing
- Ixabepilone, Paclitaxel, Cyclophosphamide
- Where
- 49 sites in United States, Argentina and 13 more
- Volunteers
- 384 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms, Breast
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer
Evaluate the activity of Trastuzumab, Lapatinib, and a combination of both agents with chemotherapy in the preoperative (neoadjuvant) treatment of early breast cancer.
- Trial name
- CHERLOB (NCT00429299)
- Testing
- lapatinib, trastuzumab, paclitaxel
- Where
- 17 sites in Germany, Italy and 1 more
- Volunteers
- 121 people
- Sponsor
- GlaxoSmithKline
Alzheimer Disease, Dementia
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- MINDFuL (NCT05318976)
- Testing
- XPro1595
- Where
- 41 sites in Australia, Canada and 6 more
- Volunteers
- 207 people
- Sponsor
- Inmune Bio, Inc.
Rheumatoid Arthritis
Safety and Efficacy of Intravenous ACZ885 and Oral Methotrexate Therapy in Patients With Early Rheumatoid Arthritis
This study was intended to evaluate the safety and efficacy of intravenous (IV) ACZ885 and oral methotrexate (MTX) therapy in patients with early rheumatoid arthritis (RA)
- Trial name
- NCT00487825
- Testing
- Canakinumab (investigational), Methotrexate (MTX)
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 78 people
- Sponsor
- Novartis
Early Alzheimer's Disease
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype.
- Trial name
- APOLLOE4 (NCT04770220)
- Testing
- Experimental: ALZ-801
- Where
- 95 sites in United States, Canada and 7 more
- Volunteers
- 325 people
- Sponsor
- Alzheon Inc.
Alzheimer´s Disease
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
The purpose of this study is to assess the efficacy and safety of lanabecestat compared with placebo administered for 104 weeks in the treatment of early Alzheimer´s disease.
- Trial name
- AMARANTH (NCT02245737)
- Testing
- Lanabecestat
- Where
- 254 sites in United States, Australia and 13 more
- Volunteers
- 2,218 people
- Sponsor
- AstraZeneca
Neoplasms, Breast
Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer
Evaluate the percentage of clinical objective responses (cOR) in patients with HER2 negative early breast cancer treated with pre operative (neoadjuvant)lapatinib and letrozole
- Trial name
- NCT00422903
- Testing
- lapatinib, letrozole
- Where
- 14 sites in Italy, Spain
- Volunteers
- 92 people
- Sponsor
- GlaxoSmithKline
Alzheimer Disease, Parkinson Disease
Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
Annovis is conducting a clinical study to investigate Posiphen in patients with Early Alzheimer's Disease (AD) and Early Parkinson's Disease (PD). Investigators are looking to recruit 68 patients in two parts of the study.
- Trial name
- NCT04524351
- Testing
- Posiphen
- Where
- 13 sites in United States
- Volunteers
- 75 people
- Sponsor
- Annovis Bio Inc.